BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11100603)

  • 1. [Attitude of primary care physicians to early detection of prostatic cancer through prostate-specific antigen].
    Oller Colom M; Jiménez Navarrete S; Hidalgo García A; Calvo Rosa E; Pérez Herrera MM; Castellanos Duarte RM; Simón Muela CI; Asens Mampel N; Duaso Allué I; Gascón Gazulla S
    Aten Primaria; 2000 Sep; 26(5):323-6. PubMed ID: 11100603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
    Murray NP; Reyes E; Tapia P; Orellana N; Dueñas R; Fuentealba C; Badinez L
    Arch Esp Urol; 2011 Dec; 64(10):961-71. PubMed ID: 22228894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for prostate cancer--how to manage in 2006?
    Lobel B
    Acta Chir Iugosl; 2005; 52(4):19-21. PubMed ID: 16673588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stratification of prostate-specific antigen level and results of transrectal ultrasonography and digital rectal examination as predictors of positive prostate biopsy.
    Clark TW; Goldenberg L; Cooperberg PL; Wong AD; Singer J
    Can Assoc Radiol J; 1997 Aug; 48(4):252-8. PubMed ID: 9282157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The digital rectal exam, prostate-specific antigen and transrectal echography in the diagnosis of prostatic cancer].
    Martínez de Hurtado J; Chéchile Toniolo G; Villavicencio Mavrich H
    Arch Esp Urol; 1995 Apr; 48(3):247-59. PubMed ID: 7538749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Is it convenient in a screening programme for prostate tumour to do biopsy in people with PSA between 3 and 3.9 ng/ml?].
    Parravicini M; Del Boca C
    Arch Ital Urol Androl; 2003 Jun; 75(2):99-101. PubMed ID: 12868147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.
    Roobol MJ; Steyerberg EW; Kranse R; Wolters T; van den Bergh RC; Bangma CH; Schröder FH
    Eur Urol; 2010 Jan; 57(1):79-85. PubMed ID: 19733959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.
    Candas B; Cusan L; Gomez JL; Diamond P; Suburu RE; Lévesque J; Brousseau G; Bélanger A; Labrie F
    Prostate; 2000 Sep; 45(1):19-35. PubMed ID: 10960839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
    Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
    Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate gland volume is a strong predictor of biopsy results in men 70 years or older with prostate-specific antigen levels of 2.0-10.0 ng/mL.
    Kobayashi T; Mitsumori K; Kawahara T; Nishizawa K; Ogura K; Ide Y
    Int J Urol; 2005 Nov; 12(11):969-75. PubMed ID: 16351653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.
    Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Dueñas R
    Arch Esp Urol; 2013 May; 66(4):335-41. PubMed ID: 23676536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
    Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
    BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].
    Cepeda Piorno J; Rivas del Fresno M; Fuente Martín E; González García E; Muruamendiaraz Fernández V; Fernández Rodríguez E
    Arch Esp Urol; 2005 Jun; 58(5):403-11. PubMed ID: 16078781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early diagnosis of prostate cancer in the Western Cape.
    Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
    S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of transrectal ultrasound guided biopsy in patients over 70 years old with a prostate specific Antigen (PSA) level ≤ 15 ng/ml and normal digital rectal examination: a 10-year prospective follow-up study of 427 consecutive patients.
    Mohamed ZK; Dominguez-Escrig J; Vasdev N; Bharathan B; Greene D
    Urol Oncol; 2013 Nov; 31(8):1489-96. PubMed ID: 22591749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.
    Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
    J Urol; 2017 Feb; 197(2S):S200-S207. PubMed ID: 28012755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.